P

    ProQR Therapeutics BV (PRQR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.13
    -0.16 (-6.99%)

    Market Cap: $323.16M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(27/40)
    Avg Surprise
    -14.24%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.11
    Range$-0.12 - $-0.10
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.14-28.7%
    60d ago$-0.14-28.7%
    30d ago$-0.14-26.9%
    7d ago$-0.14-26.9%
    Current$-0.11
    Revenue Consensus
    $5M
    Range$3M - $6M
    5 analysts
    Dec 31, 2026
    EPS Consensus$0.01
    Range$-0.08 - $0.09
    2 analysts
    Revenue Consensus
    $4M
    Range$-4487840 - $8M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.01---
    Sep 26EST
    		-$-0.11---
    Jun 26
    		$-0.10$-0.14+28.57%Beat+28.6%
    Mar 26
    		$-0.15$-0.18+16.67%Beat-36.4%
    Dec 25
    		$-0.09$-0.09-4.63%Miss-2.9%
    Sep 25
    		$-0.12$-0.17+29.41%Beat-50.0%
    Jun 25
    		$-0.14$-0.08-75.00%Miss-250.0%
    Mar 25
    		$-0.11$-0.16+31.25%Beat-10.0%
    Dec 24
    		$-0.09$-0.09+4.86%Beat-28.6%
    Sep 24
    		$-0.08$-0.14+42.86%Beat+0.0%
    Jun 24
    		$-0.04N/A+76.47%Beat+63.6%
    Mar 24
    		$-0.10$-0.16+37.50%Beat+23.1%
    Dec 23
    		$-0.07$0.01-800.00%Miss+56.3%
    Sep 23
    		$-0.08$-0.13+38.46%Beat+72.4%
    Jun 23
    		$-0.11$-0.12+8.33%Beat+52.2%
    Mar 23
    		$-0.13$-0.10-30.00%Miss+35.0%
    Dec 22
    		$-0.16$-0.16+0.00%Beat+42.9%
    Sep 22
    		$-0.29$-0.23-26.09%Miss-20.8%
    Jun 22
    		$-0.23$-0.22-4.55%Miss+17.9%
    Mar 22
    		$-0.20$-0.24+16.67%Beat+33.3%
    Dec 21
    		$-0.28$-0.12-133.33%Miss-7.7%
    Sep 21
    		$-0.24$-0.24+0.00%Beat+22.6%
    Jun 21
    		$-0.28$-0.27-3.70%Miss-211.1%
    Mar 21
    		$-0.30$-0.30+0.00%Beat+14.3%
    Dec 20
    		$-0.26$-0.25-4.00%Miss+33.3%
    Sep 20
    		$-0.31$-0.39+20.51%Beat+8.8%
    Jun 20
    		$-0.09N/A+74.29%Beat+73.5%
    Mar 20
    		$-0.35$-0.36+2.78%Beat+12.5%
    Dec 19
    		$-0.39$-0.35-11.43%Miss-2.6%
    Sep 19
    		$-0.34$-0.38+10.53%Beat-61.9%
    Jun 19
    		$-0.34$-0.43+20.93%Beat-25.9%
    Mar 19
    		$-0.40$-0.38-5.26%Miss+0.0%
    Dec 18
    		$-0.38$-0.26-46.15%Miss+17.4%
    Sep 18
    		$-0.21$-0.31+32.26%Beat+57.1%
    Jun 18
    		$-0.27$-0.47+42.55%Beat+50.9%
    Mar 18
    		$-0.40$-0.40+0.00%Beat+20.0%
    Dec 17
    		$-0.46$-0.48+4.17%Beat-15.0%
    Sep 17
    		$-0.49$-0.50+2.00%Beat-6.5%
    Jun 17
    		$-0.55$-0.51-7.84%Miss-
    Mar 17
    		$-0.50$-0.51+1.96%Beat-
    Dec 16
    		$-0.40$-0.53+24.53%Beat-
    Sep 16
    		$-0.46$-0.54+14.81%Beat-

    Key Metrics

    Valuation
    P/E Ratio-4.07EV/EBITDA-2.10x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-228.20%Operating Margin-100.70%
    ROE-57.40%ROIC-63.82%
    Financial Health
    Debt/Equity0.06xInterest CoverageN/A
    Current Ratio3.49xQuick Ratio3.49x
    Trading Statistics
    Beta0.03Avg Volume986.77K
    52-Week High$3.1052-Week Low$1.33

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.29
    SMA 20$2.09
    SMA 50$1.88
    SMA 200$1.79
    EMA 10$2.23
    EMA 20$2.12
    EMA 50$1.93
    EMA 200$1.84

    MACD

    Line: 0.14Signal: 0.13Hist: 0.00

    ADX

    ADX: 33.7+DI: 26.0-DI: 16.2

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down4.0
    PSAR$2.46

    Bollinger Bands

    Upper Band$2.53
    Lower Band$1.65
    %B Position4202%(Upper)
    Band Width0.55

    RSI (14-Day)

    Neutral
    53.9

    Momentum Oscillators

    Stoch %K67.1
    Stoch %D76.6
    Williams %R-52.4
    ROC (10d)10.4%
    Momentum0.20
    CCI (20d)34.1
    MFI (14d)60.4

    Volatility Measures

    ATR (14d)$0.14(6.6%)
    StdDev (20d)0.22
    Hist Vol72.4%(High)

    Volume Flow

    VWAP$2.18
    OBV3.1M
    AD Line-11.9M
    CMF (20d)0.148

    Volume Metrics

    Avg Vol (20d)1.0M
    Vol Ratio0.9x
    VWMA (20d)$2.14

    Pivot Points

    R3$2.41
    R2$2.38
    R1$2.33
    Pivot Point$2.31
    S1$2.26
    S2$2.23
    S3$2.19

    Advanced Oscillators

    TSI29.74
    Ultimate Osc57.6
    KST262.10

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$8.90M$2.07M$4.64M$2.92M$3.82M$4.52M$4.31M$3.84M$6.30M$4.45M$3.28M$1.37M
    Cost of Revenue$718,705$705,412$672,631N/AN/AN/AN/AN/A$714,596$695,067N/AN/A
    Gross Profit$8.19M$1.36M$3.97M$2.92M$3.82M$4.52M$4.31M$3.84M$6.30M$4.45M$3.28M$1.37M
    Operating Expenses$17.15M$15.23M$13.01M$14.20M$16.07M$15.34M$14.39M$12.56M$9.90M$12.53M$9.55M$8.76M
    R&D$12.88M$12.02M$9.83M$11.08M$11.41M$12.32M$10.61M$9.41M$7.05M$9.28M$7.73M$5.45M
    SG&A$0$3.85M$3.89M$3.12M$4.82M$3.23M$3.91M$3.28M$3.01M$3.45M$4.75M$3.31M
    Operating IncomeN/A$-13,873,452$-9,039,430$-11,284,000$-12,249,000$-10,816,000$-10,081,000$-8,716,000$-3,600,000$-8,075,000$-6,268,000$-7,391,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$2,594$2,872$276,708$10,558
    Income Before Tax$-8,847,095$-13,603,078$-8,835,362$-11,006,000$-12,161,000$-10,079,000$-9,305,000$-8,108,000$-2,892,000$-7,655,000$-5,478,000$-5,379,001
    Income Tax Expense$25,413$1,000$0$0$18,000$0$0$0$-200,000$3,000$5,000$40,999
    Net Income$-8,872,510$-13,603,078N/A$-11,006,000$-12,179,000$-10,079,000$-9,305,000$-8,108,000$-2,692,000$-7,658,000$-5,483,000$-5,710,000
    EBITDAN/A$-12,897,666$-8,366,798$-10,335,000$-11,486,000$-9,401,000$-5,821,000$-8,166,000$-2,178,406$-6,961,128$-291,000$-4,726,443
    EBITN/A$-13,603,078$-9,039,429$-11,006,000$-12,161,000$-10,079,000$-6,492,000$-8,854,000$-2,889,406$-7,652,128$-1,019,000$-5,368,443
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PRQR

    News

    Certain Common Stock of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026.

    Certain common stock of ProQR Therapeutics N.V. are currently under a 60-day lock-up agreement, which began on June 25, 2026, and will end on August 24, 2026. This agreement restricts officers and directors from selling or transferring their ordinary shares or convertible securities without the consent of BofA Securities, Evercore Group, and Cantor Fitzgerald & Co. The lock-up is designed to maintain share price stability following a recent offering or event.

    www.marketscreener.com•8/24/26•
    Neutral

    Certain Warrants of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026.

    Certain warrants of ProQR Therapeutics N.V. are currently under a lock-up agreement, which began on June 25, 2026, and is set to expire on August 24, 2026. During this period, officers and directors are restricted from directly or indirectly selling, pledging, or otherwise disposing of ordinary shares or convertible securities without prior written consent from BofA Securities, Inc., Evercore Group L.L.C., and Cantor Fitzgerald & Co. This lock-up is designed to manage the sale of company securities by insiders following specific events.

    www.marketscreener.com•8/24/26•
    Neutral

    ProQR Therapeutics starts with Buy rating on strong RNA editing data and upcoming clinical milestones.

    ProQR Therapeutics has received a Buy rating due to promising phase 1 results for its AX-0810 drug, showing an 8-fold increase in serum bile acids, which suggests potential for treating biliary atresia. The company anticipates several key clinical milestones by early 2027, including full phase 1 data for AX-0810 and results for AX-0811. With strong cash reserves and a partnership with Eli Lilly, ProQR is well-positioned for significant value growth.

    Pluang•8/22/26•
    Bullish

    Price to sales forward of ProQR Therapeutics N.V. – FWB:0PQ

    The article focuses on the "Price to sales forward" financial metric for ProQR Therapeutics N.V., traded on the Frankfurt Stock Exchange under the symbol 0PQ. It appears to be a stub or a section from a larger financial data platform, providing a heading for this specific financial data point without presenting the actual numerical values.

    TradingView•8/20/26•
    Neutral

    PRQR Looks 1.8% Undervalued on GF Value™ at $2.45

    Bank of America Securities initiated coverage on ProQR Therapeutics NV (PRQR) with a buy rating and an $8 price target, validating its Axiomer RNA-editing platform. Despite its early development stage, unprofitability, and negative cash flow, the stock is considered moderately undervalued by GuruFocus's GF Value™ at $2.45, with strong insider buying indicating management confidence. The company’s GF Score™ of 50/100 highlights strengths in valuation and momentum, balanced by concerns in financial strength.

    GuruFocus•8/20/26•
    Bullish

    Frequently Asked Questions About PRQR

    Does PRQR pay dividends?
    ProQR Therapeutics BV (PRQR) does not currently pay a regular dividend.
    What is PRQR's market cap?
    ProQR Therapeutics BV (PRQR) has a market capitalization of $323.16M with a current stock price of $2.13.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In